Ketorolac is found to help prevent cancer cell metastasis
Last Update: 2020-06-19
Search more information of high quality chemicals, good prices and reliable suppliers, visit
But coins always have two sidesCancer therapy is also a double-edged swordThese cancer therapies may induce the body's inflammatory reaction or immunosuppressive injury reaction, and these stress reactions will give cancer cells a "chance to succeed" in metastasis, thus causing cancer cell proliferation, cancer recurrence, and even death< br / > how to treat cancer better? How to avoid cancer metastasis and recurrence? How to make patients reduce disease and prolong life? These problems have always been the "difficult and miscellaneous diseases" that perplex cliniciansHowever, a recent paper published in the Journal of clinical investigation may be able to "suit the case"< br / > < br / > the study was conducted by DrVikas Psukhatme, Dean of Emory University School of medicine, in collaboration with DrDipak panigrahy and DrAllison gartung of Beth Israel Deaconess Medical CenterThey found that giving an anti-inflammatory drug, called ketorolac, before surgery can effectively trigger the immune system to eliminate cancer cell metastasis, thereby prolonging the survival of animal models of cancer metastasis[br / > DrVikas Psukhatme image source: Emory University < br / > preoperative administration of anti-inflammatory drugs can prevent the spread of cancer cells < br / > ketorolac is a cheap NSAID (non steroidal anti-inflammatory drugs), which has analgesic, anti-inflammatory, antipyretic and anti platelet aggregation effectsIts analgesic effect is similar to that of aspirin and morphineIt is also concerned that its side effects are as strong as opioids or anesthetics, so it is only approved by the FDA for "short-term pain management." < br / > what really sparked Dr sukhatme's "brilliant idea" was that ketorolac was "different" from other NSAIDs: it preferentially inhibited COX-1 enzyme, not COX-2At present, the prevention of cancer recurrence is mainly focused on COX-2 inhibitors, but the experimental value of COX-1 is not considered < br / > therefore, researchers are on the way to prove whether ketorolac can be a new drug to inhibit cancer recurrence The researchers designed a mouse experiment to test whether ketorolac, an anti-inflammatory drug, can effectively avoid inflammation after cancer treatment? Can it further inhibit the spread and metastasis of cancer cells? < br / > < br / > the researchers used the mouse model of metastatic lung cancer to observe the metastasis of cancer cells after primary tumor resection The study found that 60% of the mice given ketorolac before operation could control the metastasis of cancer cells on the 43rd day after operation, and the remaining 40% of the mice showed a long-term survival state beyond 90 days In contrast, ketorolac did not show the advantage of prolonging the survival rate in the control group, and all the mice given ketorolac after surgery spontaneously developed cancer cell metastasis on the 25th day after tumor resection, and their lives were in danger < br / > ketorolac and resolvins are more effective in the coordinated treatment < br / > in order to determine whether the stimulation of inflammatory regression can prevent tumor recurrence and / or inhibit the growth of micrometastasis, the researchers gave resolvins (a natural anti-inflammatory factor produced by human body) through osmotic pump two hours before tumor resection Surprisingly, compared with intraoperative drug delivery, preoperative drug delivery can also accelerate the regression of inflammation, effectively prolong the survival rate after tumor resection, and show the most effective antitumor activity < br / > preoperative administration of resolvins can effectively eliminate the micrometastasis of tumor and prevent the sleep escape stimulated by surgery < br / > in addition, the researchers also found that ketorolac and resolvins can make the mice after primary tumor resection show better antitumor activity, greatly improve the survival rate, and effectively avoid the inflammation caused by surgery or chemotherapy to stimulate the dormant cancer cells to active cancer cells < br / > "But now we urgently need clinical trials to verify the results of this study, maybe it will become a new effective means to inhibit the recurrence of cancer." < br / > reference materials: < br / >  proactive stimulation of resolution and information blockade eradicates micrometabases < br / >  anti information approach shows promise for preventing cancer metadata approach cancer metadata
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to firstname.lastname@example.org
. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.